Recent Annual Reports

Browse the latest SEC filings with AI-powered analysis. Get insights into corporate performance, financial trends, and business developments.

📊 3391 Reports

🤖 AI Analyzed

Recent

📄 Page 188 of 283

Eledon Pharmaceuticals, Inc.

10-K March 19, 2026

Key Highlights

Completed enrollment for the Phase 2 LIGHTHOUSE study for ALS in Q3 2025, with m...
Shared positive early results from the Phase 2 OPTIMIZE study for kidney transpl...
Successfully raised $45.0 million through a public share offering in Q2 2025, si...

Read Analysis

🤖 AI Generated

ASSEMBLY BIOSCIENCES, INC.

10-K March 19, 2026

Key Highlights

Trades on The Nasdaq Global Select Market under the ticker symbol ASMB.
Designated as a "Non-accelerated filer" and a "Smaller reporting company," offer...

Read Analysis

🤖 AI Generated

FRANCO NEVADA Corp

40-F March 19, 2026

Key Highlights

Operates a unique gold-focused royalty and streaming model, acting as a speciali...
Manages a large and diverse portfolio of over 400 assets worldwide, spanning pre...
Actively pursues growth through strategic acquisitions and financing of developm...

Read Analysis

🤖 AI Generated

Kolibri Global Energy Inc.

40-F March 19, 2026

Key Highlights

Boosted oil and gas production by 15% with successful drilling program and new w...
Generated 7% more cash from daily business, reaching $41.5 million in 2025.
Doubled investments in new equipment and drilling to $62.6 million, signaling co...

Read Analysis

🤖 AI Generated

AMERICAN BATTERY MATERIALS, INC.

10-K March 19, 2026

Key Highlights

Achieved 204% revenue growth to $15.2 million in 2025, driven by pilot recycling...
Secured a multi-year supply deal worth up to $50 million with a major European E...
Opened first commercial pilot battery recycling plant in Nevada and received a k...

Read Analysis

🤖 AI Generated

DarioHealth Corp.

10-K March 19, 2026

Key Highlights

Expanded digital mental health services and user base through the $200 million a...
Strong B2B2C model with partnerships (employers, health plans, providers) and st...
Possesses valuable technology and customer relationships, primarily from Twill, ...

Read Analysis

🤖 AI Generated

TECOGEN INC.

10-K March 19, 2026

Key Highlights

Specializes in clean power products, specifically efficient combined heat and po...
Products offer energy efficiency, cost savings, and lower carbon emissions for b...
Benefits from government incentives, rebates, and tax breaks promoting clean ene...

Read Analysis

🤖 AI Generated

BLUE BIOFUELS, INC.

10-K March 19, 2026

Key Highlights

Successfully scaled pilot plant and secured a $1.15 million DOE grant, validatin...
Formed a 50-50 joint venture, VertiBlue Fuels, to build a Sustainable Aviation F...
Their CTS technology is highly efficient (3,500 gallons/acre vs. 600 for corn et...

Read Analysis

🤖 AI Generated

RELMADA THERAPEUTICS, INC.

10-K March 19, 2026

Key Highlights

Successful strategic pivot to new drug candidates, NDV-01 for bladder cancer and...
NDV-01 showed strong 76% (83% statistical) complete response at 12 months in Pha...
Sepranolone reduced tic severity by 28% and improved quality of life by 69% in T...

Read Analysis

🤖 AI Generated

COMM 2012-CCRE4 Mortgage Trust

10-K March 19, 2026

Key Highlights

COMM 2012-CCRE4 is a CMBS "pass-through" trust distributing commercial loan paym...
Two key loans, Prince Building and Eastview Mall, generated strong Net Operating...
The trust's financial health is directly tied to the performance of its underlyi...

Read Analysis

🤖 AI Generated

electroCore, Inc.

10-K March 19, 2026

Key Highlights

Successful diversification into chronic pain and consumer wellness markets throu...
Launched next-generation gammaCore Emerald in early 2023, enhancing core product...
Strategic focus on online sales and direct-to-consumer channels to expand market...

Read Analysis

🤖 AI Generated

Galera Therapeutics, Inc.

10-K March 19, 2026

Key Highlights

Successfully executed a bold strategic pivot, selling old drug assets and acquir...
New pan-NOS inhibitor for breast cancer is in a NIH-funded Phase 1/2 trial, with...
Secured $2.9 million investment for the acquisition and has potential for up to ...

Read Analysis

🤖 AI Generated

Stay Informed with AI Analysis

Get comprehensive insights from annual reports with our AI-powered analysis. Track corporate performance, financial trends, and strategic developments.

Back to Homepage